Canada: Federal Court Of Appeal Finds That PMPRB Extends To Generics

On Nov. 6, 2015, the Federal Court of Appeal issued a rare decision relating to Canada's pricing control regime for patented medicines administered by the Patented Medicine Prices Review Board ("PMPRB"). The Court of Appeal's decision sheds light on the scope of the PMPRB's jurisdiction over non-patent owners, such as generic drug companies, and addresses the constitutional validity of section 79(1) of the Patent Act.

The appeal arose from two decisions of Justice O'Reilly in the Federal Court1, where the court allowed two applications for judicial review and set aside two decisions of the PMPRB.

One case concerns the generic company ratiopharm (now Teva) and its anti-asthmatic drug ratio HFA, a generic version of GlaxoSmithKline's ("GSK's") Ventolin HFA®. ratiopharm sold ratio HFA pursuant to an exclusive license from GSK, which allowed ratiopharm to set the price of the drug in Canada.

The other case concerns the generic company Sandoz, a wholly-owned subsidiary of Novartis. Novartis authorized Sandoz to sell generic versions of certain Novartis drugs, although no written license agreement between Novartis and Sandoz governed these sales.

While the PMPRB addressed a variety of issues in each case, the Federal Court and Federal Court of Appeal decisions were limited to two issues: (1) whether non-patent owners, and in particular generic drug companies such as ratiopharm and Sandoz, can be "patentees" under section 79(1) of the Patent Act; and (2) whether the legislation governing the PMPRB (i.e., sections 79-103 of the Patent Act) is constitutionally valid. Notably, the decisions did not address the question of the scope of the PMPRB's jurisdiction based on the interpretation of whether a patent "pertains to" a medicine.

"Patentee" under section 79(1) of the Patent Act can include non-patent owners

The PMPRB held that both ratiopharm and Sandoz were "patentees" and therefore fell within the jurisdiction of the PMPRB. This finding was based on the broad definition of "patentee": "the person for the time being entitled to the benefit of the patent for that invention."

According to the PMPRB, ratiopharm was considered a "patentee" of ratio HFA because it had the right to sell the medicine pursuant to the license agreement with GSK. Sandoz was considered a "patentee" because it had an implied license from Novartis to sell the medicines at issue.

The Federal Court found these decisions to be unreasonable and instead limited the PMPRB's jurisdiction to patent owners. A primary focus of the Federal Court's decision was its view that the constitutional validity of the PMPRB was rooted in Parliament's exclusive jurisdiction over patents. Accordingly, extending the PMPRB's jurisdiction to non-patent owners would put the constitutional validity of the PMPRB into question. Notably, the Federal Court did not expressly find that the PMPRB would be unconstitutional if its jurisdiction were extended in this manner. The constitutional validity of the PMPRB was merely put into question.

The Federal Court of Appeal disagreed with the Federal Court's analysis. The errors included a failure to give sufficient deference to the PMPRB's decision. While both Courts found that the standard of review in dispute was reasonableness, the Federal Court substituted its own view for that of the PMPRB.

The Federal Court of Appeal stated that a reasonableness review requires the Court to consider whether the decision under review meets the threshold of acceptability and defensibility and the lower court erred in failing to do so.

In finding that non-patent holding generics can be considered to be "patentees" for PMPRB purposes, the Federal Court of Appeal concluded that:

the extent to which a given company relies on patent protection in its overall business model as innovator companies typically do and generic companies typically do not, is irrelevant to the question whether, with respect to a particular medicine being sold, it is acting as a patentee within the meaning of subsection 79(1) of the Act.

The PMPRB is constitutionally valid

Both ratiopharm and Sandoz argued that the PMPRB is unconstitutional at least to the extent that the PMPRB retains jurisdiction over generic pharmaceutical products. According to this argument, the current regime is one of pure price regulation, which intrudes into the Province's constitutional jurisdiction over property and civil rights.

The PMPRB, the Federal Court, and the Federal Court of Appeal all agreed that the PMPRB was constitutionally valid at least to the extent that it has jurisdiction over patented medicines sold by patent owners.

However, the Federal Court questioned the constitutional validity of the PMPRB as it relates to non-patent owners. The Federal Court did not make any conclusions in this regard, since the Court found that the PMPRB's jurisdiction does not extend this far.

The Federal Court of Appeal, on the other hand, took its analysis a step further and found that the PMPRB is constitutionally valid as it relates to non-patent owners. According to the Court of Appeal, there is no basis to undercut the integral connection between the PMPRB and patents when the drug company targeted holds a licence to sell a patented medicine without owning the patent. The court found that the PMPRB seeks to prevent the harm arising by reason of the existence of the patent pertaining to the medicine being sold. Therefore, nothing turns on the fact that the person exercising the selling rights does not hold the patent itself.

The disputes between the PMPRB and both ratiopharm and Sandoz, which began in 2008 and 2010, respectively, are not finished. The Federal Court of Appeal remitted the matter back to a different judge of the Federal Court to decide (1) the propriety of the $65,898,842.76 pricing adjustment directed against ratiopharm to offset excess revenues realized on the sale of ratio HFA; and (2) whether the respective patents in each case pertain to the medicines in issue. The Federal Court's decision, and subsequent appeal decisions, on these issues may have a larger impact for the drug industry as they have the potential to rule on both the criteria for what is excessive pricing as well as the scope of the PMPRB's jurisdiction over patented medicines under the phrase a "patent pertaining to a medicine."

Footnotes

1 For a concise article summarizing the Federal Court decisions, see Patented Medicines Prices Review Board Jurisdiction is Limited by the Federal Court.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Smart & Biggar/Fetherstonhaugh
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions